Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants
Gabe MBN, Fuhr R, Sinn A, Eliasen A, Berthelsen KK, Kuhlman AB, Bækdal TA, Nejad AB
Diabetes, Obesity and Metabolism (2024) · n=105
The thorough-QT study that cleared cagrilintide at the 4.5 mg dose for cardiac repolarisation safety — the regulatory-grade ECG study that closes the QT-prolongation question Phase 3 trials cannot answer at their resolution.
This is the regulatory-grade thorough-QT (TQT) study for cagrilintide, the dedicated cardiac-repolarisation safety trial that the FDA requires for any chronic-dosing molecule with the kind of plasma exposure CagriSema produces. Investigators conducted a double-blind, randomised, placebo-controlled trial in 105 healthy participants (53 cagrilintide, 52 placebo). Participants received escalated cagrilintide doses up to 4.5 mg weekly or matched placebo over a multi-week dosing period; ECGs were collected at 12, 24, 48, and 72 hours post-dose at steady state, and QTcF intervals (Fridericia-corrected QT) were analysed against the ICH E14 regulatory threshold. The primary endpoint was whether the upper limit of the two-sided 90% confidence interval for the placebo-adjusted change-from-baseline QTcF fell below 10 ms — the ICH E14 threshold below which a drug is considered to lack clinically relevant QT-prolongation risk.
The trial met the negative-result endpoint cleanly. No clinically relevant QTcF prolongation was observed at any timepoint or dose, with the upper confidence-interval bound below the 10 ms threshold across all measurement windows. The authors concluded that cagrilintide is not associated with clinically relevant QTc prolongation and does not carry increased risk of ventricular tachyarrhythmias attributable to repolarisation effects at therapeutic exposure. This is the result that closes the cardiac-repolarisation question Phase 3 trials cannot answer at their resolution — Phase 3 ECG monitoring in REDEFINE-1 (Garvey et al. 2025) and REDEFINE-2 (Davies et al. 2025) is not designed to detect single-digit-millisecond QT effects, which is why the FDA requires a dedicated TQT study designed at the resolution needed to clear the ICH E14 threshold.
The TQT result is one of several class-clearing safety studies that travel with any modern long-acting metabolic peptide entering Phase 3. For CagriSema, the GLP-1-receptor-mediated long-tail safety questions (pancreatitis, gallbladder disease, NAION, medullary thyroid carcinoma class signal, the suicidal-ideation review) travel with the semaglutide component and rest on the SUSTAIN, STEP, and SELECT safety packages (Marso et al. 2016, Wilding et al. 2021, Lincoff et al. 2023). The amylin-component long-tail safety questions — particularly any signals that might not show up in the semaglutide package — rest on a thinner evidence base, with this TQT study and the broader Phase 2 / Phase 3 adverse-event profile as the primary inputs.
Thorough-QT studies are designed to clear a specific regulatory question at a specific resolution; they are not designed to address chronic-dosing safety, drug-drug interactions outside the dosing window, or rare arrhythmia events. The 105-participant sample size is appropriate for the ICH E14 framework (powered to exclude a 10 ms upper-bound effect) but limits any extension to subgroup safety analysis. The healthy-participant design — required by ICH E14 to remove confounding from concurrent disease and medication — does not address how cagrilintide might behave in adults with underlying cardiac disease, electrolyte abnormalities, or concurrent QT-prolonging medications, all of which are over-represented in the real-world chronic-obesity-therapy population. The TQT framework characterises the effect at therapeutic exposure with single-agent administration; the result does not formally clear CagriSema (cagrilintide + semaglutide combined) for repolarisation effects, which would require either a dedicated combination TQT study or reliance on the individual TQT clearances for both agents plus PK-interaction evidence from the Phase 1b co-administration trial (Enebo et al. 2021). The trial is single-sponsor (Novo Nordisk) and follows the standard industry-conducted TQT design; independent replication is not the norm for TQT studies and has not been published for cagrilintide. The result clears the specific repolarisation question the FDA requires; broader long-term cardiovascular safety depends on the cardiovascular-outcome trials in the CagriSema program rather than on this paper.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.